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We investigated the separate and combined effects of a behavioral intervention and meth-
ylphenidate (Ritalint) on disruptive behavior and task engagement in 3 children with
severe to profound mental retardation. The behavioral intervention involved differential
reinforcement of appropriate behavior and guided compliance. All 3 children demon-
strated decreased disruptive behavior and improved task engagement in response to the
behavioral intervention. Two of the 3 children demonstrated similar improvement in
response to methylphenidate. Although both interventions were highly effective for these
2 participants, the relative efficacy of the interventions varied between the 2 children.
There was no evidence of an additive or synergistic effect of the two interventions, but
the high efficacy of each intervention alone limited our ability to detect such effects.
DESCRIPTORS: disruptive behavior, children with mental retardation, drug effects,
methylphenidate, differential reinforcement, guided compliance
Disruptive behavior in individuals with
mental retardation is a common clinical
problem that is treated by a variety of pro-
fessionals including behavior analysts and
physicians. Physicians frequently prescribe
medications to decrease disruptive behavior
(Gadow, 1985), whereas behavior analysts
use a variety of behavioral procedures (Har-
ris & Ersner-Hershfield, 1978; Matson &
Gorman-Smith, 1986). Despite the wide-
spread use of both pharmacologic and be-
havioral approaches to treatment, with the
exception of a few studies (Fisher, Piazza, &
Page, 1989; Johnson, Handen, Lubetsky, &
Sacco, 1994; Schell et al., 1986), it is un-
common for physicians and behavior ana-
lysts to collaborate in evaluating the efficacy
of these interventions. Potential benefits of
collaboration would include (a) more rigor-
ous measures of behavioral effects and side
effects than are usually found in pharmaco-
logic studies, (b) use of experimental designs
that are capable of investigating treatment
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effects on individual subjects, and (c) in-
creased investigation of the relative efficacy
of behavioral and pharmacologic treatments
when used alone and in combination
(Schroeder, 1985).
Widespread use of neuroleptic medica-
tions for individuals with mental retardation
has been criticized because of studies in
which participants have shown behavioral
improvement when medication was discon-
tinued (Heistad, Zimmermann, & Doebler,
1982) and because of the potential of such
medications to cause irreversible movement
disorders or other severe side effects (Whi-
taker & Rao, 1992). Despite these concerns,
neuroleptic medications continue to be the
psychotropic medication used most fre-
quently in persons with mental retardation
(Baumeister, Todd, & Sevin, 1993; Gadow,
1985). Given that overactive behavior is one
of the primary reasons for treatment with
neuroleptics (Gadow, 1985), stimulant med-
ications such as methylphenidate may be an
effective alternative (Aman, Marks, Turbott,
Wilsher, & Merry, 1991).
Stimulant medications are used to treat
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attention deficit hyperactivity disorder
(ADHD) in 1% to 2% of school-age chil-
dren in the United States (Safer & Krager,
1988). Early studies of the use of stimulants
to treat persons with mental retardation sug-
gested that they were ineffective (Aman,
1982). However, more recent placebo-con-
trolled studies suggested that children with
mild to moderate mental retardation and hy-
peractive behaviors respond to stimulants in
a manner similar to children with normal
intelligence and ADHD (Aman et al., 1991;
Handen, Breaux, Gosling, Ploof, & Feld-
man, 1990; Handen et al., 1992). Children
with mental retardation may have an in-
creased risk of side effects such as tics and
social withdrawal (Handen, Feldman, Gos-
ling, Breaux, & McAuliffe, 1991; Helsel,
Hersen, & Lubetsky, 1989). However, in
contrast to the side effects of neuroleptics,
the side effects of stimulants are usually re-
versible when the medication is withdrawn.
Research on the effects of methylpheni-
date on persons with severe to profound
mental retardation is limited. Aman et al.
(1991) found that only 1 of 13 children and
adolescents with an IQ of less than 45 and
ADHD or conduct disorder had a beneficial
response to methylphenidate. However, only
a 0.4 mg/kg dose of methylphenidate was
assessed in this study. In a placebo controlled
study of 29 adolescents and adults with se-
vere to profound mental retardation, Aman
and Singh (1982) found no beneficial re-
sponse to 0.3 mg/kg and 0.6 mg/kg doses
of methylphenidate on a variety of rating
scales and observations of ward behavior.
However, the participants enrolled in this
study displayed a variety of disruptive be-
haviors, including stereotypic behaviors,
which one would not expect to respond to
methylphenidate. Moreover, the group ex-
perimental design did not allow determina-
tion of whether individual subjects may have
benefited from the medication. There are re-
ports of beneficial effects of stimulants for
some individuals with severe to profound
mental retardation, but these reports have
not used experimental designs (Spencer,
1970; Triantafillou, 1972).
In contrast, there is an extensive behav-
ioral literature on the treatment of disruptive
behaviors in persons with mental retardation
(Harris & Ersner-Hershfield, 1978). In this
literature, differential reinforcement proce-
dures (including differential reinforcement
of alternative behavior; DRA) are the most
frequently described intervention for de-
creasing problem behaviors (Lennox, Mil-
tenberger, Spengler, & Erfanian, 1988). Dif-
ferential reinforcement has been shown to be
effective in decreasing stereotyped behavior
(Mulhern & Baumeister, 1969), inappropri-
ate verbalizations (Deitz & Repp, 1973;
Konczak & Johnson, 1983), disruptive class-
room behaviors (Deitz, Repp, & Deitz,
1976), and aggressive and self-injurious be-
haviors (Repp & Deitz, 1974). Although the
potential of differential reinforcement pro-
cedures to decrease problem behaviors is
clear, the success of this intervention de-
pends on the identification of effective re-
inforcers and maintaining variables that can
be altered (Vollmer & Iwata, 1992). Fur-
thermore, behavioral treatments may not al-
ways reduce the disruptive behaviors to zero
or near-zero levels (Repp & Deitz, 1974;
Sewell, McCoy, & Sewell, 1973) and may
require very high frequencies of reinforce-
ment (Mulhern & Baumeister, 1969) that
may be difficult to implement in the home
and school environments.
Given the advantages and disadvantages
of pharmacologic and behavioral treatments,
it is important to investigate the relative ef-
ficacy of these interventions and the possi-
bility that combining behavioral and phar-
macologic treatments will result in additive
or interactive effects (Pelham & Murphy,
1986). Studies of groups of children with
ADHD provide some support for the addi-
tive effects of methylphenidate and behav-
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ioral treatments (Carlson, Pelham, Milich,
& Dixon, 1992; Pelham, Milich, & Walker,
1986), but the extent to which these effects
are seen in individual children is less clear
(Schell et al., 1986). In this study we inves-
tigated the separate and combined effects of
methylphenidate and a behavioral treatment
involving differential reinforcement and
guided compliance in decreasing the disrup-
tive behaviors of 3 children with mental re-
tardation.
METHOD
Subjects and Setting
Three children with severe to profound
mental retardation participated in this study.
All engaged in severe disruptive and aggres-
sive behaviors and were admitted to an
eight-bed inpatient hospital unit dedicated
to the treatment of severe behavior disorders
in individuals with developmental disabili-
ties. Treatment sessions were conducted by
graduate students or trained behavior ana-
lysts who worked with the children individ-
ually. Sessions were conducted in a dormi-
tory-style room (4.5 m by 6.0 m) that served
as the children’s living quarters. It was
equipped with a full bathroom, a table (180
cm long), two to four beds, and three to five
chairs. Participants were enrolled in the
study after obtaining written parental in-
formed consent.
Ted. Ted was a 6-year-old boy with severe
mental retardation whose aggressive and dis-
ruptive behaviors included hitting, kicking,
and throwing or knocking over objects and
furniture. His mother reported that his dis-
ruptive and aggressive behaviors occurred
several times every day at both home and
school, but were most evident at home. She
stated that he had been ‘‘hyperactive’’ since
he was an infant. Ted had never taken med-
ications for his behavior. He lived with his
mother, stepfather, and two siblings. He
communicated using approximately seven
signs and a variety of gestures. He could fol-
low one-step commands and eat with uten-
sils, but did not independently use the toilet.
On the Revised Gesell Developmental
Schedules (Knobloch, Stevens, & Malone,
1987), his adaptive and language skills were
estimated to be at 21 months.
Bill. Bill was an 11-year-old boy with pro-
found mental retardation whose aggressive
and disruptive behaviors included pulling
hair, hitting, and throwing objects at others
or off shelves. He was described by his
mother as very active, often climbing on
people and jumping on furniture. These be-
haviors occurred several times per day at
home. Bill’s behavior had been treated with
thioridazine in the past without improve-
ment. He was taking no medications at the
time of his admission. Bill lived with his par-
ents and five siblings, two of whom also had
mental retardation. He communicated pri-
marily by using gestures and pointing. He
imitated single-syllable words by using
grunts of various intonations and could fol-
low simple one-step commands. Bill re-
quired assistance with all personal care skills.
He could eat with his fingers, but not with
utensils. He could help with dressing by put-
ting his arms through the sleeves of a shirt
and by pulling up his pants.
Art. Art was a 7.5-year-old boy with frag-
ile X syndrome, severe mental retardation,
and a seizure disorder. His anticonvulsant
(valproic acid) dose was not changed during
the study. He was admitted for the treatment
of aggressive and disruptive behaviors that
included hitting, biting, pinching, and spit-
ting at his parents and others. Prior to his
admission to this hospital, he had been ad-
mitted to an inpatient psychiatric unit for
treatment of these behaviors. During the
psychiatric hospitalization, his aggressive be-
haviors had been treated with risperidone,
but his parents were concerned that he
seemed to be sedated. Art was weaned off
the risperidone before this investigation was
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begun. Art communicated using multiword
sentences. On the Revised Gesell Develop-
mental Schedules (Knobloch et al., 1987),
his adaptive skills were at 36 months. On
the Peabody Picture Vocabulary Test (Dunn
& Munn, 1981), his age-equivalent score
was 27 months (standard score less than 40).
Dependent Variables and Data Collection
Ted and Bill. The primary dependent
measure for Ted and Bill was the percentage
of time engaged in disruptive behavior dur-
ing 10-min task sessions in which they were
asked to place plastic blocks or books into a
specific container. Disruptive behaviors were
defined as throwing objects, climbing on or
under furniture, knocking over furniture,
swinging doors open and closed repeatedly,
or attempting to destroy objects by ripping,
stomping, or kicking them. Data were col-
lected on laptop computers using Portable
Computer Systems For Observational Use
software. The duration of disruptive behav-
ior was measured from the onset of the dis-
ruptive behavior until the child had not en-
gaged in any disruptive behavior for 5 s. In-
terobserver agreement was obtained on an
average of 38% (Ted) and 32% (Bill) of ses-
sions across all phases and conditions of the
experiment. Total agreement was calculated
as the exact overlap in the length of time (in
seconds) that two independent observers
agreed on the presence of disruptive behav-
ior plus the exact overlap in the length of
time that they agreed on the absence of dis-
ruptive behavior divided by the length of the
session (600 s) and multiplied by 100%. For
Ted, mean agreement (with ranges in paren-
theses) for disruptive behavior during base-
line conditions was 96% (85% to 100%) on
placebo and 98% (87% to 100%) on 0.3
mg/kg of methylphenidate. During the
DRA and guided compliance intervention,
mean agreement for disruptive behavior was
89% (63% to 100%) on placebo and 99%
(93% to 100%) on 0.3 mg/kg of methyl-
phenidate. For Bill, mean agreement for dis-
ruptive behavior during baseline conditions
was 94% (87% to 99%) on placebo, 98%
(96% to 99%) on 0.3 mg/kg of methyl-
phenidate, and 98% (97% to 100%) on 0.6
mg/kg of methylphenidate. During the
DRA and guided compliance intervention,
mean agreement for disruptive behavior was
96% (88% to 100%) on placebo, 98%
(97% to 99%) on 0.3 mg/kg of methyl-
phenidate, and 99% (97% to 100%) on 0.6
mg/kg of methylphenidate.
Engagement with the task, defined as the
child’s picking up or walking with a toy or
book in the direction of the container or de-
positing a toy or book in the container, was
also measured. Engagement was coded from
the onset of the behavior until these behav-
iors were discontinued for at least 5 s. Cod-
ing of engagement was also stopped if the
child exhibited disruptive behaviors, received
physical guidance from the therapist, or held
a toy or book for longer than 5 s without
attempting to deposit it in the container. In-
terobserver agreement for engagement was
calculated in the same manner as described
for disruptive behavior. For Ted, mean
agreement for engagement during baseline
conditions was 99% (97% to 100%) on pla-
cebo and 98% (86% to 100%) on 0.3
mg/kg of methylphenidate. During the
DRA and guided compliance intervention,
mean agreement for engagement was 88%
(33% to 100%) on placebo and 98% (89%
to 100%) on 0.3 mg/kg of methylphenidate.
For Bill, mean agreement for engagement
during baseline conditions was 93% (87%
to 99%) on placebo, 88% (87% to 88%) on
0.3 mg/kg of methylphenidate, and 94%
(91% to 100%) on 0.6 mg/kg of methyl-
phenidate. During the DRA and guided
compliance intervention, mean agreement
for engagement was 95% (85% to 98%) on
placebo, 94% (90% to 97%) on 0.3 mg/kg
of methylphenidate, and 97% (95% to
99%) on 0.6 mg/kg of methylphenidate.
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Art. The primary dependent measure was
the rate of disruptive behaviors during a
number or letter identification task. Disrup-
tive behavior was measured as a rate rather
than as a percentage of time, because Art’s
disruptive behaviors tended to be discrete
events of short duration. Disruptive behav-
iors were defined as described above. How-
ever, because Art had to sit at a table to en-
gage in this task, getting up from the table
was also coded as a disruptive behavior. En-
gagement was defined as holding or looking
at task materials. It was measured from the
onset of the behavior until Art did not en-
gage in the behavior for 5 s. If Art held the
task material for longer than 5 s without
looking at it, he was not considered to be
engaged with the task. Data were collected
on laptop computers as described above. In-
terobserver agreement was obtained on an
average of 23% of the sessions across all
phases of the experiment. For disruptive be-
havior, interobserver agreement was calculat-
ed on a point-by-point basis (House, House,
& Campbell, 1981). Counts of disruptive
behaviors within 10-s intervals were com-
pared for two independent observers, and
the number of agreements was divided by
the total number of agreements plus dis-
agreements and multiplied by 100%. Dur-
ing baseline conditions, mean agreement for
disruptive behavior was 91% (76% to
100%) on placebo, 96% (93% to 100%) on
0.3 mg/kg of methylphenidate, and 100%
on 0.6 mg/kg of methylphenidate. During
the DRA and guided compliance interven-
tion, mean agreement for disruptive behav-
ior was 95% (92% to 97%) on placebo,
91% (77% to 100%) on 0.3 mg/kg meth-
ylphenidate, and 100% on 0.6 mg/kg meth-
ylphenidate. For engagement, interobserver
agreement was calculated by the observa-
tional software as described above. During
baseline conditions, mean agreement for en-
gagement was 92% (88% to 100%) on pla-
cebo, 96% (93% to 100%) on 0.3 mg/kg of
methylphenidate, and 92% (agreement re-
corded in only one session) on 0.6 mg/kg of
methylphenidate. During the DRA and
guided compliance intervention, mean
agreement for engagement was 93% (90%
to 97%) on placebo, 86% (59% to 100%)
on 0.3 mg/kg of methylphenidate, and 97%
(agreement recorded in only one session) on
0.6 mg/kg of methylphenidate.
Procedures
Baseline. During each baseline session for
Ted and Bill, the therapist pointed to a spe-
cific block and the designated box and said,
‘‘Put the block in this box.’’ If the child
complied with the request, the therapist is-
sued the next request upon completion of
the task. If the child did not comply with
the request, the therapist repeated the re-
quest 30 s later. Disruptive behaviors were
ignored during this condition.
During baseline sessions with Art, the
therapist presented him with two letters or
three numbers and said, ‘‘Point to the . . .’’
(a letter or number). If he did not respond
within 5 s, the therapist repeated the direc-
tion. If he did not respond to this second
instruction within 5 s, he was shown the
correct answer. When Art pointed to a card
or after he was shown the correct answer,
another trial with a different set of letters
and numbers began. No reinforcement for
task completion was provided. The therapist
did not respond to disruptive behaviors.
However, if Art got up from the table, the
therapist brought him back.
DRA and guided compliance. During each
session for Ted and Bill, the therapist asked
the child to complete the task described
above. If the child complied with the re-
quest, the therapist provided a reinforcer,
and the next request was made after the
child was given the reinforcer. If the child
did not comply with the request, he was
physically guided to complete the task and
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the next request was issued immediately
upon completion.
Art was given the instructions described
above. If he pointed to either card, he was
given verbal praise. If he pointed to the cor-
rect card, he also received an edible rein-
forcer on a variable-ratio (VR) 3 schedule. If
he did not respond to the second verbal in-
struction, hand-over-hand physical guidance
was used to assist him in pointing to the
designated number or letter.
For Ted, verbal praise and physical atten-
tion were initially used as reinforcers, but
when they appeared to be ineffective, the re-
inforcers were changed to verbal praise and
edible items. For Bill and Art, a forced-
choice preference assessment (Fisher et
al.,1992) was used to identify reinforcers.
Ten stimuli (a combination of edible items,
solitary play items, and interactive play
items) were presented two at a time, and the
child was allowed 30 s of access to the stim-
ulus he selected. The pairings were presented
in a randomized order, and each stimulus
was paired with all other stimuli one time.
The three stimuli selected most frequently
were chosen as reinforcers. For both Bill and
Art, the three most highly preferred stimuli
were all edible items (small piece of a cookie
or cracker, or a piece of cereal).
Methylphenidate. Each child was random-
ly assigned to receive a placebo (A), a 0.3
mg/kg dose of methylphenidate (B), and a
0.6 mg/kg dose of methylphenidate (C), in
one of the following four orders: ABACA(B
or C), ACABA(B or C), BACA(B or C), or
CABA(B or C). The methylphenidate dose
was rounded to the nearest 2.5 mg, and
identical capsules containing methylpheni-
date or a placebo were prepared by the hos-
pital pharmacy. The child received one cap-
sule at 8 a.m. and one at noon. All sessions
were conducted 1 to 3 hr after the child re-
ceived the capsule. All members of the treat-
ment team, participants in the study, and
family members were blind to the order of
medication administration during the first
four phases of the study. At the end of the
fourth phase, one physician was unblinded
in order to instruct the pharmacy about
what medication to prepare for the final
phase. This was done to allow within-subject
replication of the most effective methylphen-
idate dose as determined during the first
four phases of the investigation. All other
members of the treatment team, study
group, and family remained blind to the
medication that the child received during
these phases.
Ted’s medication schedule was random-
ized in the ACABA(B or C) order, but he
had side effects to the medication (tics) on
the first day that the 0.6 mg/kg dose of
methylphenidate was given. When the tics
occurred, one physician was unblinded to
medication conditions and instructed the
pharmacy to continue with the study using
an ABAB design. All other members of the
treatment team remained blind to medica-
tion conditions. Bill’s and Art’s medication
schedules were both randomized in the
BACA(B or C) order.
Experimental Design
The baseline sessions and the DRA and
guided compliance sessions were conducted
each day of the study. They were counter-
balanced in a multielement design across all
medication phases. The order of the sessions
each day was randomized. Methylphenidate
and the placebo were alternated in a reversal
design for the most effective methylpheni-
date dose.
RESULTS
Ted
Figure 1 shows the percentage of disrup-
tive behavior during each session. Initially,
verbal praise and physical attention were
used as reinforcers in the DRA intervention,
but when they appeared to be ineffective, the
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Figure 1. Percentage of each task session engaged in disruptive behaviors (Ted, Bill) or number of disruptive
behaviors per hour during each session (Art). Baseline conditions (open squares) were counterbalanced with a
differential-reinforcement-of-alternative-behavior and guided compliance (DRA 1 GC) intervention across all
methylphenidate (MPH) and placebo phases. The open circles indicate that praise and attention were the
reinforcers, and the filled circles indicate that verbal praise and an edible item were the reinforcers.
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reinforcers were changed to verbal praise and
food for the remainder of the study. During
Phase 2 on placebo with the DRA and guid-
ed compliance intervention, disruptive be-
havior occurred during an average of 11.3%
of each session. In baseline sessions during
this phase, disruptive behavior occurred dur-
ing 61.4% of each session.
On the 0.6 mg/kg dose of methylpheni-
date (Phase 3), only two data points were
obtained because Ted developed tics, and he
was tearful or crying much of the day. These
side effects were resolved on the 0.3 mg/kg
dose of methylphenidate, and thus only the
efficacy of the 0.3 mg/kg dose of methyl-
phenidate was further assessed.
During Phase 4 on the 0.3 mg/kg dose of
methylphenidate, disruptive behavior oc-
curred during an average of 1.7% of each
session with the DRA and guided compli-
ance intervention and during an average of
44.6% of each session in baseline. During
the return-to-placebo conditions, disruptive
behavior increased to an average of 82.3%
of each session in baseline, but there was no
reversal of disruptive behavior in the sessions
with the behavioral intervention. During
Phase 6, on methylphenidate at the 0.3
mg/kg dose, disruptive behavior occurred
during 65.2% of each session under baseline
conditions and remained at near-zero levels
with the DRA and guided compliance in-
tervention. Although the behavioral inter-
vention was clearly effective, the 0.3 mg/kg
dose of methylphenidate did not have a clin-
ically significant effect.
Engagement data are shown in Figure 2.
Although engagement initially seemed to
improve on methylphenidate, this effect was
not replicated during the reversal phase.
During Phase 2, the DRA and guided com-
pliance intervention resulted in engagement
during an average of 31.2% of each session.
In both phases that combined the DRA in-
tervention with methylphenidate, mean en-
gagement improved to over 90% of each ses-
sion. However, even when methylphenidate
was withdrawn, the DRA and guided com-
pliance intervention continued to result in
similarly high levels of engagement.
Bill
The results in Figure 1 show that the 0.6
mg/kg dose of methylphenidate (Phase 3)
was more effective in decreasing disruptive
behaviors than the 0.3 mg/kg dose (Phase
1). During Phase 2 on placebo, Bill was dis-
ruptive an average of 56.6% of the time dur-
ing baseline sessions, compared to an average
of 20.2% of the time during sessions with
the DRA and guided compliance interven-
tion. During Phase 3, treatment with the 0.6
mg/kg dose of methylphenidate suppressed
disruptive behavior to an average of 2.7% of
each session under baseline conditions and
an average of 1.5% of each session with the
behavioral intervention. During return to
the placebo, disruptive behavior increased to
an average of 31.4% of each session during
baseline conditions, but remained at a low
level during sessions with the behavioral in-
tervention. Reintroduction of methylpheni-
date at the 0.6 mg/kg dose replicated the
decrease in disruptive behavior during base-
line sessions. Medication and the DRA and
guided compliance intervention were not
more effective than the medication alone.
During the first placebo phase, the DRA and
guided compliance intervention alone was
not as effective as it was during the second
placebo phase. However, during the second
placebo phase, the DRA and guided com-
pliance intervention alone was approximate-
ly as effective as the 0.6 mg/kg dose of meth-
ylphenidate alone. Although both treatments
were effective when used alone, there was no
evidence of an additive effect when the treat-
ments were used together.
Engagement data are shown in Figure 2.
During Phase 2 while on placebo, engage-
ment occurred during an average of 16.5%
of each session under baseline conditions
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Figure 2. Mean percentage of each session engaged in the task for the baseline condition and the differential
reinforcement and guided compliance (DRA 1 GC) conditions across all methylphenidate (MPH) and placebo
conditions. Bars indicate ranges.
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and 45.9% of each session with the DRA
and guided compliance intervention. Treat-
ment with the 0.6 mg/kg dose of methyl-
phenidate did not further improve engage-
ment during sessions combined with the be-
havioral intervention, but did improve en-
gagement in baseline sessions.
Art
The results in Figure 1 indicate that the
0.6 mg/kg dose of methylphenidate (Phase
3) was more effective than the 0.3 mg/kg
dose (Phase 1) in suppressing disruptive be-
havior. In the first placebo condition, dis-
ruptive behaviors occurred an average of
39.6 times per hour during baseline sessions
and 3.4 times per hour in sessions with the
DRA and guided compliance intervention.
During the next phase of the study on the
0.6 mg/kg dose of methylphenidate, disrup-
tive behavior did not occur in any baseline
session and occurred at an average rate of
1.5 per hour during sessions with the be-
havioral intervention. When the medication
was withdrawn, disruptive behaviors oc-
curred at an average rate of 105.6 per hour
during baseline sessions and 15.0 per hour
during sessions with the behavioral interven-
tion. Reintroduction of the medication sup-
pressed disruptive behaviors to near-zero lev-
els under both conditions. Methylphenidate
alone and the behavioral treatment alone
were very effective at decreasing disruptive
behaviors. During the second placebo phase,
the behavioral treatment was not as effective
as it was during the first placebo phase.
Thus, in general, it appears that the medi-
cation alone may have been somewhat more
effective than the DRA and guided compli-
ance intervention alone.
Engagement data are shown in Figure 2.
During the first placebo phase, Art was en-
gaged with the task during an average of
91.4% of each session with the DRA and
guided compliance intervention and 42.2%
under baseline conditions. Treatment with
the 0.6 mg/kg dose of methylphenidate in-
creased engagement to over 90% under
baseline conditions. There was no additional
effect of the behavioral intervention.
DISCUSSION
This study demonstrates the use of single-
subject experimental methodology to inves-
tigate the separate and combined effects of
a behavioral and pharmacologic intervention
concurrently. The multielement design al-
lows comparison of baseline and behavioral
treatment alone conditions during placebo
phases and comparison of methylphenidate
alone and combined treatment during meth-
ylphenidate phases. Methylphenidate and
placebo phases were compared using a with-
in-subject reversal design. Methylphenidate
has a rapid onset of action (within 30 min)
and short duration of action (3 to 4 hr) that
allow for rapid within-subject reversals
(Greenhill, 1995).
This is one of only a few studies (Johnson
et al., 1994; Schell et al., 1986) that have
used single-subject experimental designs that
allow a controlled comparison of baseline
conditions, a behavioral intervention alone,
methylphenidate alone, and the combina-
tion of methylphenidate and a behavioral in-
tervention for the treatment of disruptive
behavior in individual subjects. It is the only
study to provide a relatively large number of
data points within each medication condi-
tion, thus allowing for a more complete eval-
uation of within-subject effects and an as-
sessment of the stabilization of data within
medication conditions. Furthermore, it is
the only study to use a single-case experi-
mental design to investigate these effects in
children with severe to profound mental re-
tardation.
For all 3 participants in this study, the
DRA and guided compliance intervention
reduced disruptive behaviors and improved
engagement with the task. For Ted, the low
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dose of methylphenidate (0.3 mg/kg) had no
clinically significant effect on disruptive be-
havior or engagement, and the high dose of
methylphenidate (0.6 mg/kg) was discontin-
ued due to side effects. For Bill and Art, the
high dose of methylphenidate decreased dis-
ruptive behavior and improved engagement
with the task. In both cases, the high dose
was much more effective than the low dose.
For Bill, high-dose methylphenidate alone
initially seemed to be more effective than
DRA and guided compliance alone, but dur-
ing the second placebo and high-dose meth-
ylphenidate phases, the two interventions
appeared to be equally effective in decreasing
disruptive behavior. Both interventions were
also effective in improving engagement with
the task. However, despite the effectiveness
of each intervention alone, there was no ev-
idence that the two interventions had an ad-
ditive or synergistic effect in decreasing dis-
ruptive behaviors or improving engagement
with the task. The effectiveness of each in-
tervention alone may have limited the pos-
sibility of detecting an additive or synergistic
effect in decreasing disruptive behavior, but
this would not explain the failure to dem-
onstrate such an effect on engagement with
the task. In Art’s case, high-dose methyl-
phenidate alone was slightly more effective
than the DRA intervention alone in decreas-
ing disruptive behavior and improving en-
gagement with the task. Methylphenidate
was so effective that the potential for a syn-
ergistic effect cannot be evaluated because of
a floor effect for disruptive behavior and a
ceiling effect for engagement.
The data demonstrate intersubject vari-
ability in the relative efficacy of the behav-
ioral and pharmacologic interventions. Ted
responded well to the DRA and guided
compliance intervention and had intolerable
side effects on the high dose of methylphen-
idate. Bill responded similarly to both inter-
ventions, and Art responded better to meth-
ylphenidate than to the behavioral interven-
tion. These findings support other studies of
individual children with mental retardation,
some of which report that behavioral inter-
ventions are more effective than methyl-
phenidate (Shafto & Sulzbacher, 1977), and
others of which report that methylphenidate
is more effective than a behavioral interven-
tion in decreasing defiant, hyperactive, or
disruptive behaviors (Johnson et al., 1994;
Schell et al., 1986). The use of reinforcer
assessments to identify effective reinforcers
for Bill and Art may help to explain the ef-
fectiveness of the behavioral interventions in
this study. However, it is noteworthy that
despite the use of a reinforcer assessment in
developing the behavioral intervention for
Art, the 0.6 mg/kg dose of methylphenidate
was more effective than the behavioral treat-
ment. The use of functional analysis and re-
inforcer assessment to develop behavioral in-
terventions to study in combination with
pharmacologic treatments is a potential area
for greater collaboration between physicians
and behavior analysts.
Other studies of children with mental re-
tardation also have failed to show an additive
or synergistic effect of methylphenidate and
behavioral treatment on disruptive behavior
or engagement with a task. Christensen
(1975) found that adding 0.3 mg/kg of
methylphenidate to a behavioral treatment
involving token and verbal reinforcement
plus extinction did not improve the class-
room behavior of 16 children with mental
retardation. Schell et al. (1986) assessed the
separate and combined effects of a behavior-
al intervention and a 0.3 mg/kg dose of
methylphenidate in a child with mild mental
retardation. They did not find an additive
effect of methylphenidate and the behavioral
intervention on defiant behavior, but they
did find an additive effect of the two inter-
ventions on correct responses to an academic
task. Similarly, in 3 children with mild men-
tal retardation, Johnson et al. (1994) found
additive effects of methylphenidate and a be-
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havioral intervention on task accuracy, but
not on measures of fidgety or defiant behav-
iors. Thus, although we did not find an ad-
ditive or synergistic effect of methylpheni-
date and the DRA and guided compliance
intervention, we cannot rule out that such
an effect may have been found had we in-
vestigated other behaviors or these behaviors
in other settings.
In contrast to the predominately single-
case studies in children with mental retar-
dation discussed above, group studies of
children with ADHD and average intelli-
gence have found that behavioral treatments
in combination with low doses of methyl-
phenidate are more effective than either in-
tervention alone (Carlson et al., 1992; Pel-
ham et al., 1986; Pelham & Murphy, 1986).
However, some studies suggest that a high
dose of methylphenidate alone is as effective
as combined treatments (Carlson et al.,
1992; Gittelman et al., 1980). The degree
to which these group studies characterize the
response of individual children to these in-
terventions is not known. This gap in the
literature highlights the need for further
studies of these effects using single-subject
experimental designs.
Interestingly, during the initial phase with
the DRA and guided compliance interven-
tion and placebo, Ted and Bill exhibited rel-
atively high rates of disruptive behaviors. In
both cases, it was during treatment with
methylphenidate that disruptive behaviors
decreased to near-zero levels. However, a re-
turn to the behavioral intervention alone did
not result in a reversal in the frequency of
disruptive behavior. In contrast, the frequen-
cy of disruptive behavior did reverse in the
baseline condition. These results suggests the
possibility that for these 2 participants,
methylphenidate facilitated learning of the
behavioral contingencies. Although a facili-
tative effect of methylphenidate on learning
behavioral contingencies has been suggested
by others (Christensen & Sprague, 1973), it
has not been clearly demonstrated. This ex-
planation for the results of our study must
be regarded as tentative, because this study
was not designed to investigate this hypoth-
esis.
This is the first report of the beneficial
effects of stimulants in children with severe
to profound mental retardation that has used
an experimental design to document the ef-
fects. It is consistent with previous case re-
ports of stimulant medications resulting in
improved behavior in this population (Spen-
cer, 1970; Triantafillou, 1972). However, in
two group studies (Aman, Kern, McGhee,
& Arnold, 1993; Aman et al., 1991), only
1 out of a total of 18 children with an IQ
of less than 45 had a beneficial response to
methylphenidate. In both studies, only a 0.4
mg/kg dose of methylphenidate was as-
sessed. Given that the response to the 0.6
mg/kg dose was much greater than the re-
sponse to the 0.3 mg/kg dose in our study,
it is possible that the low response rate in
the previous studies was related to the rela-
tively low dose of methylphenidate that was
used. Aman and Singh (1982) used both 0.3
mg/kg and 0.6 mg/kg doses of methylphen-
idate in a group of adolescents and adults
with severe to profound mental retardation
and reported no benefit for either dose, but
the group experimental design may not have
allowed detection of individuals who bene-
fited from the medication. Alternatively, the
response to medication in adults with severe
to profound mental retardation may be dif-
ferent from the response in children.
The findings of this study show the idi-
osyncratic character of response to methyl-
phenidate and to behavioral treatment in
children with severe to profound mental re-
tardation. The findings suggest that individ-
uals who conduct interventions for disrup-
tive behaviors in this population should con-
sider both behavioral and pharmacologic ap-
proaches. When considering the use of
methylphenidate, one should remember that
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children with mental retardation have been
reported to have a higher incidence of side
effects than is found in the general popula-
tion (Aman et al., 1991; Handen et al.,
1991). This may be especially true of social
withdrawal, which is a commonly reported
side effect in children with mental retarda-
tion (Handen et al., 1991; Helsel et al.,
1989), but is not frequently found in chil-
dren of average intelligence (Ahmann et al.,
1993; Barkley, McMurray, Edelbrock, &
Robbins, 1990). Due to this higher rate of
side effects and the difficulty in predicting
which children’s behavior will improve on
stimulants, it is necessary to carefully mon-
itor for efficacy and side effects when chil-
dren with mental retardation are given
methylphenidate. It is likely that this can be
best accomplished if physicians and behavior
analysts collaborate on the clinical manage-
ment of these individuals.
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STUDY QUESTIONS
1. What are some disadvantages of operant and pharmacological approaches to the treatment
of behavior disorders, and what potential benefits might result from an integrative approach?
2. What were the target behaviors and how were they measured?
3. Describe the contingencies in effect during the baseline and the DRA plus guided compliance
conditions.
4. Briefly describe the medication dosages that were evaluated and the general method of
administration.
5. What types of experimental designs were used to evaluate the effects of the behavioral and
pharmacological interventions?
6. What were the effects of each treatment separately on disruptive behavior and task engage-
ment for Ted, Bill and Art, and which treatment was more effective for each subject?
7. The authors indicated that there was no evidence of an interactive or synergistic effect
resulting from combined treatment. What type of outcome would have suggested an inter-
action effect, and what feature of the results may have obscured such an effect?
8. The authors mention that they used a preference assessment to aid in the identification of
reinforcers used during treatment. What additional analysis may have been helpful in de-
veloping the behavioral interventions or in interpreting the results if the behavioral inter-
vention had been less effective than it was?
Questions prepared by SungWoo Kahng and Michele Wallace
